Adcendo has raised a $33M Series A extension funding round to develop therapies for underserved cancer patients.
The company has raised $55M in total Series A funding.
- Adcendo aims to deploy multiple varieties of antibody-drug conjugates that kill cancer cells.
- Different varieties of this therapy solution are currently being used in over 10 clinical trials.
- Pontifax Venture Capital, Novo Holdings, and Ysios Capital led the funding round, with participation from RA Capital Management, HealthCap, and Gilde Healthcare.
- The company aims to deploy the funding toward developing therapies for sarcoma cancer.
- Adcendo was founded in 2017 as a spin-out of The University of Copenhagen and Rigshospitalet.
- Adcendo is based in Copenhagen, Denmark.
